Richard A. Slayden

6.0k citations

85 papers · 4.7k indexed · h-index 37

Co-authors: Clifton E. Barry Richard Lee Peter J. Tonge Susan E. Knudson Gurdyal S. Besra Iwao Ojima Benjamin G. Schroeder Divya Awasthi
Topics: Tuberculosis Research and Epidemiology (42 papers)Mycobacterium research and diagnosis (23 papers)Cancer therapeutics and mechanisms (15 papers)
Cited by: Infectious Diseases Molecular Medicine Epidemiology
Journals: Science Proceedings of the National Academy of Sciences Journal of the American Chemical Society
Partner nations: United States Germany United Kingdom

In The Last Decade

Richard A. Slayden

82 papers receiving 4.6k citations

Peers

Countries citing papers authored by Richard A. Slayden

Since Specialization

Citations

This map shows the geographic impact of Richard A. Slayden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A. Slayden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A. Slayden more than expected).

Fields of papers citing papers by Richard A. Slayden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard A. Slayden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A. Slayden. The network helps show where Richard A. Slayden may publish in the future.

Co-authorship network of co-authors of Richard A. Slayden

This figure shows the co-authorship network connecting the top 25 collaborators of Richard A. Slayden. A scholar is included among the top collaborators of Richard A. Slayden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard A. Slayden. Richard A. Slayden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Anti-Mycobacterial Activity of Bacterial Topoisomerase Inhibitors with Dioxygenated Linkers 2025 ·ACS Infectious Diseases ·Mark J. Mitton‐Fry,Jason E. Cummings,(unknown),(unknown),Jo Ann W. Byl,(unknown),Allison Bauman,Gregory T. Robertson,Neil Osheroff,Richard A. Slayden	0
2	Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment 2025 ·Frontiers in Pharmacology ·Jason E. Cummings,Lisa K. Woolhiser,(unknown),(unknown),Adele Romano,(unknown),John T. Belisle,Nicholas D. Walter,Gregory T. Robertson,Richard A. Slayden	0
3	A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection 2022 ·Frontiers in Immunology ·Savannah M. Rocha,Anna C. Fagre,(unknown),Jason E. Cummings,Tawfik Aboellail,Philip Reigan,(unknown),(unknown),Katriana A. Popichak,Rebekah C. Kading,Tony Schountz,Neil D. Theise,Richard A. Slayden,Ronald B. Tjalkens	9
4	TPR1, a novel rifampicin derivative, demonstrates efficacy alone and in combination with doxycycline against the NIAID Category A priority pathogen Francisella tularensis 2021 ·JAC-Antimicrobial Resistance ·Jason E. Cummings,(unknown),Richard A. Slayden	2
5	New Investigations with Lupane Type A-Ring Azepane Triterpenoids for Antimycobacterial Drug Candidate Design 2021 ·International Journal of Molecular Sciences ·О. Б. Казакова,Roxana Racoviceanu,Anastasiya V. Petrova,Marius Mioc,(unknown),(unknown),Mihai Udrescu,(unknown),Jason E. Cummings,Gregory T. Robertson,Diane Ordway,Richard A. Slayden,Codruţa Şoica	10
6	Immune Modulation as an Effective Adjunct Post-exposure Therapeutic for B. pseudomallei 2016 ·PLoS neglected tropical diseases ·(unknown),Maryam F. Afzali,Jason E. Cummings,Marie E. Legare,Ronald B. Tjalkens,Chris Allen,Richard A. Slayden,William H. Hanneman	17
7	Anomaly Detection in Host Signaling Pathways for the Early Prognosis of Acute Infection 2016 ·PLoS ONE ·Kun Wang,Stanley Langevin,Corey S. O’Hern,Mark D. Shattuck,(unknown),Adriana Forero,Juliet Morrison,Richard A. Slayden,Michael G. Katze,Michael Kirby	15
8	Cell division inhibitors with efficacy equivalent to isoniazid in the acute murineMycobacterium tuberculosisinfection model 2015 ·Journal of Antimicrobial Chemotherapy ·Susan E. Knudson,Divya Awasthi,Kunal Kumar,Alexandra Carreau,(unknown),Sophie Lagrange,(unknown),Iwao Ojima,Richard A. Slayden	21
9	Adeno-associated virus gene therapy vector scAAVIGF-I for transduction of equine articular chondrocytes and RNA-seq analysis 2015 ·Osteoarthritis and Cartilage ·(unknown),C. Wayne McIlwraith,Richard A. Slayden,R. Jude Samulski,Laurie R. Goodrich	14
10	In vitro–in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis 2014 ·Tuberculosis ·Susan E. Knudson,Kunal Kumar,Divya Awasthi,Iwao Ojima,Richard A. Slayden	25
11	Benzimidazole-based antibacterial agents against Francisella tularensis 2013 ·Bioorganic & Medicinal Chemistry ·Kunal Kumar,Divya Awasthi,Seung-Yub Lee,Jason E. Cummings,Susan E. Knudson,Richard A. Slayden,Iwao Ojima	35
12	MazF6 toxin of Mycobacterium tuberculosis demonstrates antitoxin specificity and is coupled to regulation of cell growth by a Soj-like protein 2013 ·BMC Microbiology ·Melissa V. Ramirez,(unknown),Rebecca Crew,Kathleen England,Richard A. Slayden	19
13	Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei 2011 ·Journal of Antimicrobial Chemotherapy ·(unknown),Jason E. Cummings,Kathleen England,Richard A. Slayden,Peter J. Tonge	26
14	Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis 2010 ·Microbes and Infection ·Luke C. Kingry,Ryan M. Troyer,Nicole L. Marlenee,Helle Bielefeldt‐Ohmann,Richard A. Bowen,Alan R. Schenkel,Steven Dow,Richard A. Slayden	13
15	Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis 2008 ·Journal of Antimicrobial Chemotherapy ·Richard A. Slayden,John T. Belisle	27
16	Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery 2008 ·Tuberculosis ·(unknown),(unknown),Qing Huang,Burcu Anil,(unknown),J.J. Truglio,Caroline Kisker,Daniel P. Raleigh,Iwao Ojima,D. L. Knudson,Peter J. Tonge,Richard A. Slayden	27
17	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Christopher W. am Ende,Susan E. Knudson,(unknown),James E. Childs,Todd J. Sullivan,(unknown),(unknown),(unknown),D. L. Knudson,Francis Johnson,Charles A. Peloquin,Richard A. Slayden,Peter J. Tonge	64
18	FtsZ: A Novel Target for Tuberculosis Drug Discovery 2007 ·Current Topics in Medicinal Chemistry ·Qing Huang,Peter J. Tonge,Richard A. Slayden,Teruo Kirikae,Iwao Ojima	59
19	Disease State Differentiation and Identification of Tuberculosis Biomarkers via Native Antigen Array Profiling 2006 ·Molecular & Cellular Proteomics ·Mark J. Sartain,Richard A. Slayden,Krishna K. Singh,Suman Laal,John T. Belisle	86
20	Mechanisms of isoniazid resistance in Mycobacterium tuberculosis 1998 ·Drug Resistance Updates ·Clifton E. Barry,Richard A. Slayden,Khisimuzi Mdluli	22

About Richard A. Slayden

Richard A. Slayden is a scholar working on Molecular Medicine, Infectious Diseases and Epidemiology, having authored 85 papers that have together received 4.7k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (42 papers), Mycobacterium research and diagnosis (23 papers) and Cancer therapeutics and mechanisms (15 papers). The work is most often cited by research in Infectious Diseases (2.4k citations), Molecular Medicine (599 citations) and Epidemiology (1.7k citations). Richard A. Slayden has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Clifton E. Barry, Richard Lee, Peter J. Tonge, Susan E. Knudson, Gurdyal S. Besra, Iwao Ojima, Benjamin G. Schroeder, Divya Awasthi, Kunal Kumar and Ying Yuan. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact